Heart failure from cancer therapy: can we prevent it?

ConclusionsSystematic evidence is needed to solidly found recommendations for cardioprotective prevention during chemotherapy. Likewise, trials on other neurohumoral drugs (spironolactone) and lipid ‐lowering approaches are required to improve protection for cardio‐oncology patients.

Source: ESC Heart Failure - July 10, 2019 Category: Cardiology Authors: Matthias Totzeck, Raluca I. Mincu, Gerd Heusch, Tienush Rassaf Tags: Original Research Article Source Type: research